2 天之前 · Pfizer and Alloy have collaborated on various antibody discovery efforts, including the use of Alloy's ATX-CLC platform. Launched in 2023 and accessible through Alloy's Antibody …

Boston, MA, February 11, 2025 — Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies …

Pfizer (NYSE:PFE) has entered into a multi-year collaboration with Alloy Therapeutics to develop a new antibody discovery platform. Under the deal, Alloy will receive an upfront payment from ...

1 天前 · Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows: - primary care products (52.3%): medicines used in internal medicine, …

1 天前 · Dans un communiqué, Alloy rappelle que Pfizer utilise depuis plusieurs années sa plateforme ATX-GxTM, un modèle murin transgénique humanisé, au même titre que plus de …

2025年1月22日 · Among a series of potential R&D program advances in 2025, Pfizer expects 13 Phase 3 program starts, 8 late-stage readouts and 4 regulatory decisions, among which …

Looking at the period from 2025 to 2030, Pfizer is facing a significant loss of exclusivity (LOE) wave that will reduce revenues by about $17-18 billion between 2026 and 2028. Bourla said the...

2018年4月3日 · Pfizer Inc. (NYSE:PFE) and Allogene Therapeutics, Inc. (Allogene) today announced that the two companies have entered into an asset contribution agreement for …